Kap-Sun Yeung

This inventor holds 55 USPTO granted patents and 12 published patent applications, plus 3 CIPO patents and 32 EPO patents, primarily in Immunomodulators (CPC class C07D). Top assignees: Bristol-Myers Squibb Compnay, Bristol Meyers Squibb Company, Viiv Healthcare UK (No. 4) Limited. Active years: 2002-2026.

USPTO Granted Patents = 55 (Patent Applications = 12)

% Patents Active = 92.7

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 32 (Patent Applications = 29)

Average Co-Inventor Count = 5.4

ph-index = 11

Forward Citations = 408(Granted Patents)

Forward Citations (Not Self Cited) = 328(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Middletown, CT (US) (2002 - 2003)
Wallingford, CT (US) (2022)
Madison, CT (US) (2004 - 2023)

Company Filing History:

52 out of 3,737

Bristol-Myers Squibb Compnay

patents

2 out of 41

Bristol Meyers Squibb Company

patents

1 out of 8

Viiv Healthcare UK (No. 4) Limited

patents

Years Active: 2002-2026

Loading Chart...

Areas of Expertise:

Immunomodulators

Hepatitis C

Macrocyclic Inhibitors

Piperazine Derivatives

Benzofuran Derivatives

Prodrugs

HCV NS5B Inhibitors

Indole Derivatives

Fused Furans

Antiviral Agents

Isoquinoline Derivatives

Antiapoptotic Bcl Inhibitors

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12715856 - Compounds useful as immunomodulators (2026-08-25),

2. 11578054 - Compounds useful as immunomodulators (2023-02-14),

3. 11414418 - Compounds useful as immunomodulators (2022-08-16),

4. 11369624 - Salts of prodrugs of piperazine and substituted piperidine antiviral agents (2022-06-28),

5. 11161837 - Benzofuran derivatives for the treatment of hepatitis C (2021-11-02),

6. 11046675 - Substituted isoquionline derivatives as immunomudulators (2021-06-29),

7. 10882844 - Compounds useful as immunomodulators (2021-01-05),

8. 10745382 - Compounds useful as immunomodulators (2020-08-18),

9. 10590105 - 1,3-dihydroxy-phenyl derivatives useful as immunomodulators (2020-03-17),

10. 10538555 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2020-01-21),

11. 10150747 - Compounds for the treatment of hepatitis C (2018-12-11),

12. 10144706 - Compounds useful as immunomodulators (2018-12-04),

13. 10143746 - Immunomodulators (2018-12-04),

14. 9879046 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2018-01-30),

15. 9850283 - Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions (2017-12-26),

Title: Innovator Spotlight: The Pioneering Work of Kap-Sun Yeung

Introduction

Kap-Sun Yeung, a prolific inventor based in Madison, CT, has made significant contributions to the field of pharmaceuticals with a remarkable portfolio of 54 patents. His groundbreaking work focuses on the development of compounds that serve as immunomodulators, offering promising solutions for the treatment of various diseases, including cancer and infectious diseases.

Latest Patents

Among his latest patents, Kap-Sun Yeung has introduced compounds that demonstrate utility as immunomodulators. These compounds, along with the compositions comprising them, exhibit potential for enhancing the body's immune response. The pharmaceutical compositions developed by Yeung have shown efficacy in combating a range of illnesses, highlighting his innovative approach to healthcare solutions.

Career Highlights

With a rich professional background, Kap-Sun Yeung has lent his expertise to renowned companies such as Bristol-Myers Squibb Company, where he has played a pivotal role in advancing pharmaceutical research and development. His contributions have not only led to the creation of novel treatments but have also paved the way for further advancements in the field of immunotherapy.

Collaborations

Throughout his career, Kap-Sun Yeung has collaborated with esteemed professionals in the industry, including notable coworkers like John F Kadow and Katharine A Grant-Young. Together, they have synergized their efforts to drive innovation and push the boundaries of medical science, fostering a culture of excellence and creativity in their shared endeavors.

Conclusion

In conclusion, Kap-Sun Yeung stands out as a pioneering inventor whose relentless pursuit of innovative solutions has significantly impacted the pharmaceutical landscape. His dedication to developing novel compounds as immunomodulators underscores his commitment to advancing healthcare and improving patient outcomes. With a proven track record of success and a passion for discovery, Yeung continues to inspire future generations of inventors in the field of life sciences.